Presence and clinical impact of human herpesvirus‐6 infection in patients with moderate to critical coronavirus disease‐19

dc.creatorLino, Katia
dc.creatorAlves, Lilian S.
dc.creatorRaposo, Jessica V.
dc.creatorMedeiros, Thalia
dc.creatorSouza, Cintia F.
dc.creatorSilva, Andrea A. da
dc.creatorPaula, Vanessa Salete de
dc.creatorAlmeida, Jorge R.
dc.date2022-01-26T18:11:41Z
dc.date2022-01-26T18:11:41Z
dc.date2021
dc.date.accessioned2023-09-26T22:21:06Z
dc.date.available2023-09-26T22:21:06Z
dc.identifierLINO, Katia et al. Presence and clinical impact of human herpesvirus‐6 infection in patients with moderate to critical coronavirus disease‐19. Journal of Medical Virology, p. 1-5, Oct. 2021.
dc.identifier1096-9071
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/50910
dc.identifier10.1002/jmv.27392
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8878214
dc.descriptionHuman herpesvirus‐6 (HHV‐6) may cause serious diseases in immunocompromised individuals. SARS‐CoV‐2/HHV‐6 coinfection has been emphasized in previous works, mostly case reports, small series, or epidemiological studies, but few are known about its real clinical outcomes. Here we present a real‐world pilot study aiming to understand the frequency and the clinical impact of HHV‐6 coinfection in moderate to critically ill patients hospitalized due to COVID‐19. SARS‐CoV‐2 and HHV‐6 were evaluated in nasopharyngeal samples at the hospital admission of suspected COVID‐19 patients. From 173 consecutive cases, 60 were SARS‐CoV‐2 positive and 13/60 (21.7%) were HHV‐6 positive after identified as the HHV‐6B species by a Sanger sequencing. The SARS‐CoV‐2+/HHV‐6+ group was younger but not significant for cardiovascular diseases, diabetes, obesity, and cancer, but significant among therapeutic immunosuppressed patients (as systemic lupus erythematosus and kidney transplant patients). In the medical records, only sparse data on cutaneous or neurological manifestations were found. Biochemical and hematological data showed only a trend towards hyperferritinemic status and lymphopenia. In conclusion, despite the impressive high frequency of HHV‐6 coinfection in SARS‐CoV‐2 positive cases, it did not impact general mortality. We suggest larger future prospective studies to better elucidate the influence of HHV‐6 reactivation in cases of COVID‐19, designed to specific assessment of clinical outcomes and viral reactivation mechanisms.
dc.formatapplication/pdf
dc.languageeng
dc.publisherWiley
dc.rightsopen access
dc.subjectCOVID-19
dc.subjectHHV‐6
dc.subjectHerpesvírus-6
dc.subjectInfecção por herpes vírus-6 humano
dc.subjectCOVID-19
dc.subjectHerpesvirus‐6
dc.subjectHHV‐6
dc.subjecthuman herpesvirus‐6 infection
dc.titlePresence and clinical impact of human herpesvirus‐6 infection in patients with moderate to critical coronavirus disease‐19
dc.typeArticle


Este ítem pertenece a la siguiente institución